ATXI
AVENUE THERAPEUTICS, INC.Company Information
- Company Name
- AVENUE THERAPEUTICS, INC.
- CIK
- CIK0001644963
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- ATXI: OTC
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- ATXI
SEC filing data through
Insider Sentiment
- Last purchase
- 2024-09-30
- Last sale
- 2024-12-02
- Shares purchased (TTM)
- 497
- Shares sold (TTM)
- 264,084
Institutional Sentiment
- As of
- 2024-12-31
- Institutional shares owned
- 192,628
- Shares outstanding
- 1,295,207
- Ownership
- 14.87%
Earnings Market Reaction
- Filing date
- 2026-08-07
- Price on filing date
- —
- 1-month reaction
- 77.19%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash And Cash Equivalents At Carrying Value | 2 | 2 | 3 | 4 | 3 | 4 | 3 | 3 | 5 | 3 | 2 | 0 | ||||||
Assets Current | ||||||||||||||||||
| Prepaid Expense And Other Assets Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 2 | 2 | 3 | 4 | 4 | 4 | 3 | 3 | 5 | 3 | 2 | 1 | ||||||
| Accounts Payable And Accrued Liabilities Current | - | - | - | - | - | - | - | - | - | - | - | 1 | ||||||
Liabilities Current | ||||||||||||||||||
| Derivative Liabilities Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | ||||||
| Liabilities Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 5 | ||||||
| Liabilities | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 5 | ||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Stockholders Equity | ||||||||||||||||||
| Stockholders Equity | 1 | 1 | 2 | 2 | 3 | 4 | 3 | 3 | 4 | 3 | 2 | -5 | ||||||
| Additional Paid In Capital | 107 | 107 | 107 | 108 | 108 | 108 | 105 | 104 | 103 | 98 | 93 | 88 | ||||||
| Retained Earnings Accumulated Deficit | -107 | -106 | -105 | -105 | -104 | -104 | -103 | -101 | -98 | -95 | -91 | -92 | ||||||
| Minority Interest | - | - | 0 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | ||||||
| Liabilities And Stockholders Equity | 2 | 2 | 3 | 4 | 4 | 4 | 3 | 3 | 5 | 3 | 2 | 1 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 75 | 75 | ||||||
| Common Stock Shares Issued | 3 | 3 | 3 | 3 | 3 | 3 | 2 | 2 | 1 | 1 | 0 | 0 | ||||||
| Shares Outstanding | 3 | 3 | 3 | 3 | 3 | 3 | 2 | 2 | 1 | 1 | 0 | 0 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialAVENUE THERAPEUTICS, INC. (ATXI) — SEC Financial Statements & Analysis
AVENUE THERAPEUTICS, INC. (ATXI) is a pharmaceutical preparations company, incorporated in DE. AVENUE THERAPEUTICS, INC. trades on OTC as: ATXI. AVENUE THERAPEUTICS, INC. (ATXI)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-07. Based on that filing, AVENUE THERAPEUTICS, INC. carries a market cap of $922.59K, a P/E ratio of -0.33x, a P/B ratio of 1.62x, a P/S ratio of 0.68x, an enterprise value of $-1.02M, and an EV/EBITDA multiple of 0.35x. On profitability, it posts an operating margin of -134.76%, a net margin of -127.49%, and a Return on Equity (ROE) of -165.19%. Per share, it reports EPS of $-0.85, diluted EPS of $-96.47, free cash flow per share of $-0.42, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -100.00% year-over-year, net income growth of -54.21% year-over-year, and EPS growth of -55.75% year-over-year. On the balance sheet, it maintains a debt-to-equity ratio of 2.47x, free cash flow of $-1.38M (TTM), and net debt of $-1.94M. Figures sourced from SEC EDGAR.
- Market Cap
- $922.59K
- P/E TTM
- -0.33x
- EPS TTM
- $-0.85
- P/B TTM
- 1.62x
- ROE TTM
- -165.19%
- Debt To Equity
- 2.47x
- Free Cash Flow TTM
- $-1.38M
- Net Revenue TTM Growth 1Y
- -100.00%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is AVENUE THERAPEUTICS, INC. in?
AVENUE THERAPEUTICS, INC. (ATXI) operates in the Pharmaceutical Preparations industry.
What exchange does ATXI trade on?
AVENUE THERAPEUTICS, INC. (ATXI) trades on the OTC.
Where is AVENUE THERAPEUTICS, INC. incorporated?
AVENUE THERAPEUTICS, INC. is incorporated in DE.
When was AVENUE THERAPEUTICS, INC. (ATXI)'s most recent SEC filing?
AVENUE THERAPEUTICS, INC. (ATXI)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-07.
What is ATXI's market cap?
AVENUE THERAPEUTICS, INC. (ATXI) has a market capitalization of $922.59K as of 2026-06-30.
What is ATXI's EPS (earnings per share)?
AVENUE THERAPEUTICS, INC. (ATXI)'s trailing twelve month EPS is $-0.85 as of 2026-06-30.
What is ATXI's ROE (return on equity)?
AVENUE THERAPEUTICS, INC. (ATXI)'s trailing twelve month Return on Equity (ROE) is -165.19% as of 2026-06-30.
What is ATXI's EV/EBITDA?
AVENUE THERAPEUTICS, INC. (ATXI)'s trailing twelve month EV/EBITDA is 0.35x as of 2026-06-30.